Key result
SPDEF overexpression enhances malignant phenotypes and lipid accumulation in ccRCC by activating ELOVL2 transcription.
Why the study?
The impact of the ETS transcription factor SPDEF in ccRCC and its involvement in lipid metabolism remained unclear.
SPDEF acts as an oncogenic transcriptional activator in ccRCC by directly upregulating ELOVL2, driving lipid metabolic reprogramming and tumor progression.
Answers are grounded in this paper and cite their sources.
SPDEF-ELOVL2 axis may identify therapeutic targets in ccRCC lipid reprogramming; leaves open clinical translation pending in vivo validation.
BACKGROUND: Characterized by cytoplasmic lipid accumulation and fatty-acid metabolic reprogramming, clear cell renal cell carcinoma (ccRCC) is closely related to tumor progression and invasion. The impact of SPDEF, an ETS transcription factor, in ccRCC and its involvement in lipid metabolism remain unclear. METHODS: SPDEF expression and prognostic relevance were analyzed using TCGA-KIRC data and validated in ccRCC tissues and cell lines. Functional experiments were conducted to evaluate influence on cell proliferation, migration, lipid metabolism, and apoptosis. Regulatory interactions with ELOVL2 were examined via transcriptomic analysis, dual-luciferase reporter assays, ChIP-qPCR, and site-directed promoter mutagenesis. RESULTS: SPDEF was significantly overexpressed and closed to higher TNM stage and unfavorable survival. The higher expression of SPDEF enhanced malignant phenotypes, increased lipid accumulation, and impeded apoptotic processes. Mechanistically, SPDEF bound to the -141 bp site of the ELOVL2 promoter, thereby activating its transcription; mutation of this site abolished activation. Altering ELOVL2 expression partially rescued or mimicked SPDEF-driven phenotypes. CONCLUSIONS: SPDEF acts as an oncogenic transcriptional activator in ccRCC by directly upregulating ELOVL2, thereby driving lipid metabolic reprogramming and tumor progression. These findings provide mechanistic insight into the SPDEF-ELOVL2 axis in lipid-associated ccRCC progression, while its clinical and translational relevance requires further validation in larger patient cohorts and clinically relevant models.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied clear cell renal cell carcinoma (ccRCC). SPDEF overexpression was evaluated on malignant phenotypes, lipid accumulation, and apoptotic processes. SPDEF overexpression enhanced malignant phenotypes and lipid accumulation in ccRCC by binding to the -141 bp site of the ELOVL2 promoter and activating its transcription.
Synapse has enriched 10 related papers. Consider them for comparative context: